Patient Concerns Over Effects of IBD Therapies on Reproductive Health Not Adequately Addressed, Study Reports

Patient Concerns Over Effects of IBD Therapies on Reproductive Health Not Adequately Addressed, Study Reports
Women's concerns over taking inflammatory bowel disease (IBD) medications during their reproductive years are not being satisfactorily addressed by physicians, according to a study that analyzed relevant social media posts. The study, “Reproductive Health and Medication Concerns for Patients With Inflammatory Bowel Disease: Thematic and Quantitative Analysis Using Social Listening,” was published in the Journal of Medical Internet Research. Treatment of IBD during a woman's reproductive years is particularly challenging because clinicians want to ensure remission during conception and pregnancy and, at the same time, protect the health of the fetus. Preterm delivery, low birth weight, and a greater risk of miscarriage are all connected with IBD activity at the time of conception. Although there is growing evidence suggesting that most medications present a low risk of complications during pregnancy and lactation, more women with IBD, particularly those with Crohn’s disease, are choosing not to have children due to concerns over therapies and their effects. Studies have also shown that a significant percentage of surveyed women with IBD said they would stop taking medications during pregnancy even if told otherwise by a physician. Social listening, which refers to examining social media and forum posts, can be effectively used to determine public attitudes and opinions on various healthcare topics. For example, the research team had previously employed social listening to assess the use of virtual reality in h
Subscribe or to access all post and page content.